by Asa Elmore | Sep 17, 2021 | News, Press Releases
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
by Asa Elmore | Sep 16, 2021 | News, Press Releases
Sutro Biopharma Announces Expansion of Leadership Team – Nicole M. Chieffo, MBA, appointed to Vice President of Clinical Operations – Werner Rubas, Ph.D., appointed to Vice President of Preclinical Development SOUTH SAN FRANCISCO, Calif., Sept. 16, 2021 –...
by Asa Elmore | Sep 1, 2021 | Events, News, Presentations, Press Releases
Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
by Asa Elmore | Aug 18, 2021 | News, Press Releases
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer SOUTH SAN FRANCISCO, August 18, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the...
by Asa Elmore | Aug 9, 2021 | News, Press Releases
Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones – Additional follow-up data on STRO-002 from the Phase 1 dose-escalation cohort were presented at ASCO June 2021; enrollment for the...
by Asa Elmore | Aug 9, 2021 | News, Press Releases
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 9, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and...
